-- 路透社周四报道称,美国生物柴油强制掺混量目标将提高至2026年的54亿加仑,迫使产量增长超过60%,原因是供应短缺和信贷紧缩威胁着柴油价格的上涨。 报道还指出,由于美国环保署(EPA)创纪录的掺混目标造成了巨大的供应压力,美国生物柴油行业在经历了疲软的一年后必须迅速扩大生产。 报道称,在与美以伊冲突相关的燃料成本上涨的背景下,美国环保署于3月下旬推出了激进的生物燃料强制掺混目标,以提振供应。 报道指出,将大豆转化为生物柴油的生产商今年需要将产量提高60%以上才能达到目标,但分析师质疑该行业能否实现这一目标。 报道称,环保署将2026年的掺混要求提高至54亿加仑,2027年提高至57亿加仑,高于2025年的33.5亿加仑。报告指出,为符合规定,今年的总供应量必须达到60.7亿加仑,因为并非所有国内生产都能产生符合规定的合规积分。 炼油商必须根据可再生燃料标准(RFS)混合生物燃料或购买可再生识别码(RN)积分,任何短缺都可能迫使他们动用储存的积分。 报告称,如果炼油商动用积分储备,合规成本可能会上升,并最终转嫁到柴油零售价格上。 报告还指出,义务方每月必须生产约9.15亿个积分,而生物柴油积分的产生量从2月份的4.81亿个增至3月份的6.51亿个。 报告补充说,美国能源信息署预测,2026年生物柴油供应量为15.2亿加仑,可再生柴油供应量为35.3亿加仑,均低于规定量。 美国清洁燃料联盟主任保罗·温特斯表示,由于生产商难以确保原料供应和管理燃料分销物流,生物柴油行业在满足新规方面面临诸多挑战。 报告指出,美国燃料和石化制造商协会表示,国内原料供应有限将限制产量并增加合规成本。 报告还指出,农业团体和农民长期以来一直敦促华盛顿提高生物燃料强制掺混比例,以支持农作物需求。 报告补充说,在11月的中期选举中,农民仍然是共和党的重要票仓。 (市场动态新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源,但可能包含传闻和推测。准确性无法保证。)
Related Articles
Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.
ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue
ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.
Research Alert: Gddy: Strong Profitability Metrics Offset By Continued Revenue Headwinds
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GDDY posted Q1 2026 revenue of $1.2B (+6%), in line with consensus, with EPS of $1.60 beating estimates of $1.52 despite booking deceleration to +2.7% from +5% in Q4. A&C segment growth of +11.6% to $498M showed resilience but continued moderating, while Core Platform remained sluggish at +2.8%. We view booking weakness as concerning given competitive pressures and small business spending constraints that raise questions about growth sustainability. Management reaffirmed 2026 revenue guidance of $5.195B-$5.275B (~6% growth), reflecting limited visibility into booking improvement. However, we see encouraging AI monetization signs with ARPU growth of +9.3% to $246 and Airo AI Builder achieving multi-million dollar annualized bookings within weeks of beta launch. We believe GDDY's impressive margin expansion with NEBITDA margins reaching 32.6% (+210 bps) demonstrates operational discipline, though sustaining A&C growth above 10% remains critical for investor confidence.